Navigation Links
Halozyme Therapeutics to Present at the Barclays 2013 Global Healthcare Conference
Date:3/5/2013

SAN DIEGO, March 5, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Barclays 2013 Global Healthcare Conference in Miami, FL. on March 12, 2013 at 4:15 p.m. ET/1:15 p.m. PT. Kurt Gustafson , Chief Financial Officer of Halozyme Therapeutics, will provide a corporate overview.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The presentation will be webcast through the "Investors" section of Halozyme's corporate website at www.halozyme.com, and a recording will be made available for 90 days following the event. To access the live webcast, please log on to Halozyme's website approximately 15 minutes prior to the presentation to register and download any necessary audio software.

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the absorption and dispersion of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA.  For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

 

Investor Contact:
Kurt Gustafson
Halozyme Therapeutics
858-704-8272
ir@halozyme.com

Media Contact:
Nurha Hindi
Hill + Knowlton Strategies
310-633-9434
Nurha.Hindi@hkstrategies.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Halozyme to Host First Quarter 2012 Financial Results Conference Call
2. Halozyme Reports First Quarter 2012 Financial Results
3. Halozyme Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
4. Halozymes Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase 2 Study Results Presented at ADA 2012
5. Halozyme Confirms Baxter Has Received A Complete Response Letter For HyQ BLA
6. Halozyme Reports Second Quarter 2012 Financial Results
7. Halozyme to Host Third Quarter Financial Results Conference Call
8. Halozyme Therapeutics To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
9. Halozyme Announced Roche Filed A Marketing Authorization Application For Subcutaneous MabThera
10. Halozyme Reports Fourth Quarter and Year End 2012 Financial Results
11. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... , May 2, 2016  Deerfield announced ... financing of Graybug Vision, Inc. Graybug Vision is ... therapies that may transform care for ocular diseases ... Graybug Vision,s technology was first developed at Johns ... a startup venture. Graybug Vision ...
(Date:5/2/2016)...  While nearly three-quarters of Americans (71%) are aware ... health, only about half report taking any steps to ... a new survey announced today by Hologic (Nasdaq: ... Osteoporosis Month, Hologic is raising awareness of this major ... Americans. Osteoporosis is a disease that causes ...
(Date:5/2/2016)... May 2, 2016  Celsion Corporation (NASDAQ: ... announced data from the first cohort of patients ... (the OVATION Study) combining GEN-1, the Company,s DNA-based ... treatment of newly-diagnosed patients with advanced ovarian cancer ... debulking surgery.  In the first three patients dosed, ...
Breaking Medicine Technology:
(Date:5/2/2016)... ... , ... Further establishing itself as a leader in natural pet products category, ... were selected from over 1,000 entrants as a winner and recipient of the prestigious ... for dogs are a favorite product among pet-parents worldwide, as each whimsical knobby shape ...
(Date:5/2/2016)... ... May 02, 2016 , ... Zitter Health Insights ... Patient Satisfaction Award that will recognize specialty pharmacies for their achievements in customer ... Insights’ Specialty Pharmacy Patient Satisfaction Survey compiled throughout 2016. Results will be published ...
(Date:5/2/2016)... ... May 02, 2016 , ... Dr. Rassouli, dentist in Orange ... decline. According to the research, which was published in the “Journal of the American ... and about 5.4 million Americans have Alzheimer’s disease. The study found that dental problems ...
(Date:5/2/2016)... ... May 02, 2016 , ... Visceral fat, also known ... the kidneys, liver and pancreas. If not properly addressed, visceral fat can lead ... Internal Medicine, Medical Oncology and Palliative Care, warns against the dangers of visceral ...
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... The 2016 World Ultimate & Guts Championship ... Camp at Manhattan College, made the cut. The WUGC is being held in London, England ... won the gold in the men’s division, another gold in the women’s masters division, and ...
Breaking Medicine News(10 mins):